Endosomal aspartic proteinases are required for invariant-chain processing
about
Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin LThe role of major histocompatibility complex molecules in luteal functionMice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cellsInvolvement of cathepsin E in exogenous antigen processing in primary cultured murine microgliaInvariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.Evolution of the mammalian MHC: natural selection, recombination, and convergent evolution.Diminished intracellular invariant chain expression after vaccinia virus infection.Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41.The cytoplasmic tail of invariant chain regulates endosome fusion and morphologyPulse-chase analysis for studies of MHC class II biosynthesis, maturation, and peptide loading.Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartmentsIi chain controls the transport of major histocompatibility complex class II molecules to and from lysosomes.Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells.Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles.T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.Inhibition of invariant chain (Ii)-calnexin interaction results in enhanced degradation of Ii but does not prevent the assembly of alpha beta Ii complexesA structural transition in class II major histocompatibility complex proteins at mildly acidic pH.Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligandsDifferential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages.HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR moleculesDegradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphismNovel mutants define genes required for the expression of human histocompatibility leukocyte antigen DM: evidence for loci on human chromosome 6pAlteration of a single hydrogen bond between class II molecules and peptide results in rapid degradation of class II molecules after invariant chain removal.Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation.LAMP-2C Inhibits MHC Class II Presentation of Cytoplasmic Antigens by Disrupting Chaperone-Mediated AutophagyGILT expression in B cells diminishes cathepsin S steady-state protein expression and activity.Autophagy and its role in MHC-mediated antigen presentation.Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM.Trimeric interactions of the invariant chain and its association with major histocompatibility complex class II alpha beta dimers.TAPBPR: a new player in the MHC class I presentation pathway.LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.Future prospects for the analysis of complex biological systems using micro-column liquid chromatography-electrospray tandem mass spectrometry.HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.Class II antigen processing compartments and the function of HLA-DM.Antigen presentation by MHC class II molecules.Association of the invariant chain with major histocompatibility complex class I molecules directs trafficking to endocytic compartments.The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease.Purification of intracellular compartments involved in antigen processing: a new method based on magnetic sorting.
P2860
Q24678337-5308D0F0-CB43-46C6-BEFD-0E88A49242FAQ24799415-32C3E391-FA32-4204-81FF-5958A3C3235BQ28295485-6EE6302D-BB7E-4814-A00A-F2DF63014700Q28589163-F3A20747-3CB5-4D8A-AF4F-DA65C0388F5FQ28776057-EDE1B118-1FAD-46E3-B743-4D30D5FC5651Q30479486-04AB5E3A-0BA1-438F-8B09-E3253C5F28C6Q33630613-3E86C64D-81C9-47FA-A398-DB9F241D1A26Q33747640-64B6E301-D7EF-48E6-9770-C8C1BF4725ACQ33829941-554515FA-3603-4784-9508-0D7A2DE06564Q33898764-CE04EDFE-1892-4F66-A03C-E4FDD38242ADQ34155809-F9F42A5A-A427-41A6-A26E-C0EAE2A91CF3Q36236708-AE3A8BD9-BDD2-40BE-8A59-6C2EA425F9DBQ36274077-AE2ACF88-3258-4712-B2B7-BDA21096BE5DQ36301521-E89C0A0E-80E2-4863-9F14-6396842952C3Q36364770-B9E09984-6537-4B9B-B208-92FCA2B88461Q36365527-E6A4F0C7-9D99-4EA9-8D0D-872511821AE5Q36365643-871ECB8A-BCED-4BC7-9823-7A6E779D9290Q36366080-05E59344-1727-4165-8971-AD29C4774B6CQ36370268-F1F86F9D-CB5A-4791-B532-EAAB4AED73AAQ36370496-CD2879CD-EF61-4B16-AB51-9212B58F5E2AQ36377428-9279E92B-8C2A-4D1D-9249-F2E871B490BFQ36380525-E13BD691-16ED-4F3C-9AD1-691156DCCDD0Q36380786-72D9E6BD-8A72-4984-BD59-CDC0859E48FBQ36401156-9A836F8C-2AC5-414B-96E1-A7BF6AD4E5DAQ36475793-A17A6F4E-29D0-4B24-A4F3-68D0276E9EDCQ36655722-364A208B-0F32-46F5-BE2F-4A9BE64F7AB0Q36996406-F4B7A094-8800-469A-A94D-0DACA6193CE2Q37315630-848932E3-DCEF-4BA4-8470-9FD0DF1B4568Q37361625-11516B41-8CF8-4F2A-BDE4-53BAB15277E8Q38352870-28EECDC0-3B63-42B0-8036-E0512A76C0CEQ38365574-88074DC4-8131-440C-8493-1D5D5267D927Q39697429-A54370A9-0EB6-4A38-BB57-7220BF66765FQ40935488-4AFA795E-AE60-4F4D-A6EC-70E74AAC9597Q40947677-BD0DF300-3DA5-4D1E-A162-C922B7AC6EC5Q41030957-592500B9-BE40-4C1C-AC80-8339DD032BCAQ41091901-5B31887F-823B-46DF-B32B-05FA9B505BD9Q41359341-EC7D3BEF-05D8-41C0-BA97-3534ED09CFA9Q41379399-4B4F4023-F8A2-4832-B79E-8F222763ABE0Q41475460-0AB7E2BE-FE0C-4B1C-9E39-364986406D7DQ42992813-CA871838-A28D-4B54-BA13-7C289673BBAD
P2860
Endosomal aspartic proteinases are required for invariant-chain processing
description
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
article publié dans les Procee ...... f the United States of America
@fr
artículu científicu espublizáu en 1994
@ast
im März 1994 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1994/03/15)
@sk
vědecký článek publikovaný v roce 1994
@cs
wetenschappelijk artikel (gepubliceerd op 1994/03/15)
@nl
наукова стаття, опублікована в березні 1994
@uk
name
Endosomal aspartic proteinases are required for invariant-chain processing
@ast
Endosomal aspartic proteinases are required for invariant-chain processing
@en
Endosomal aspartic proteinases are required for invariant-chain processing
@nl
type
label
Endosomal aspartic proteinases are required for invariant-chain processing
@ast
Endosomal aspartic proteinases are required for invariant-chain processing
@en
Endosomal aspartic proteinases are required for invariant-chain processing
@nl
prefLabel
Endosomal aspartic proteinases are required for invariant-chain processing
@ast
Endosomal aspartic proteinases are required for invariant-chain processing
@en
Endosomal aspartic proteinases are required for invariant-chain processing
@nl
P2093
P2860
P356
P1476
Endosomal aspartic proteinases are required for invariant-chain processing
@en
P2093
J. S. Blum
M. A. Marić
M. D. Taylor
P2860
P304
P356
10.1073/PNAS.91.6.2171
P407
P577
1994-03-15T00:00:00Z